Executive Summary

The medical technology (medtech) industry is navigating a complex landscape of persistent cost pressures, evolving care pathways, and rapid technological integration. As 2026 approaches, five interconnected trends are redefining the competitive dynamics of the sector: the expansion of volume-based procurement (VBP) in mainland China, the accelerating migration of procedures to outpatient and ambulatory surgery centers (ASCs), the strategic imperative of supply chain resilience, the far-reaching impact of GLP-1 therapies, and the shift toward platform-based competition. These forces are not isolated; they reflect a broader global recalibration of how medical devices are priced, distributed, and deployed. For multinational corporations, healthcare providers, and investors, understanding these trends is essential to navigating a market increasingly shaped by geopolitical and economic pressures.

Introduction

For decades, medtech companies relied on premium pricing and hospital-centric care models to drive growth. That logic is being upended. In mainland China, a national procurement program has moved beyond its original intent of cost containment to become a market-structuring mechanism with global echoes. In the United States, regulatory changes are accelerating the shift of high-acuity procedures into outpatient settings, rewriting the economics of device sales. Meanwhile, tariffs and trade disputes are compelling companies to rethink decades-old supply chain assumptions. Even therapeutic innovations — notably GLP-1 receptor agonists — are altering patient volumes across multiple surgical and monitoring categories.

These changes are not ephemeral. They represent a structural evolution in the global medtech industry, one that demands a more sophisticated analysis of market access, value propositions, and technological integration.

Background & Context

The medtech industry has historically been a bastion of steady growth, underpinned by aging populations and technological innovation. However, the post-pandemic era has brought new vulnerabilities: fiscal constraints on healthcare systems, heightened awareness of supply chain dependencies, and a wave of technology-enabled disruption. As a result, medtech companies are being compelled to move beyond a product-centric approach toward an ecosystem-based strategy.

Clarivate’s annual analysis of medtech trends, which relies on proprietary data and expert insights, identifies the key forces likely to shape the sector in 2026. This article builds on those findings to explore their international relevance and strategic implications.

Main Analysis

1. Mainland China’s VBP Expansion: A New Global Price Benchmark

Mainland China’s volume-based procurement program has evolved from a targeted cost-containment effort into a powerful instrument of industrial policy and market regulation. The latest national round introduced more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational companies, the program now influences pricing expectations not only in China but across emerging markets, where procurement officials often look to China as a reference.

Why it matters internationally: China’s VBP is accelerating the growth of domestic medtech champions while squeezing foreign players into narrower, lower-margin niches. Multinationals must adapt portfolio strategies, streamline cost structures, and reconsider which product categories remain viable in a price-constrained environment. The spillover effect is already visible in other Asian markets, where similar bulk procurement models are being explored.

2. Outpatient and ASC Settings: The New Center of Gravity for Procedures

The migration of surgical procedures from hospitals to outpatient settings is not new, but it is now reaching a critical mass. In the United States, CMS’s 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list. This opens the door for higher-acuity procedures—such as cardiac ablation—to be performed in lower-cost settings.

Why it matters internationally: Although this policy is U.S.-specific, it reflects a global trend toward value-based care and site-of-care shifts. In Europe, Japan, and other mature markets, similar pressures to reduce costs and improve patient outcomes are driving procedures to ambulatory settings. Medtech companies must redesign products for portability, ease of use, and lower-cost environments, while aligning commercial models with the needs of ASCs and outpatient clinics.

3. Supply Chain Resilience: From Efficiency to Strategic Security

Trade tensions, tariff exposure, and fluctuating material costs have made supply chain resilience a board-level priority for medtech companies. Long-standing assumptions about offshoring and just-in-time manufacturing are being replaced by a focus on diversification, nearshoring, and multi-region footprints. Larger manufacturers are leveraging scale and vertical integration to buffer against volatility, creating a competitive divide between those that can invest in resilience and those that cannot.

Why it matters internationally: Global health systems depend on a fragile supply chain for critical devices. Disruptions have exposed vulnerabilities in semiconductors, specialty metals, and active pharmaceutical ingredients. Governments are responding with policies aimed at securing key medical technologies, which in turn affects trade flows and foreign direct investment. Companies that fail to adapt may find themselves locked out of markets or facing prohibitive tariffs.

4. GLP-1 Therapies: Reshaping Care Pathways Beyond Weight Loss

The rapid adoption of GLP-1 receptor agonists for weight management and glycemic control is having ripple effects across medtech. Bariatric surgery volumes are under pressure, though the impact varies by procedure type. Downstream effects are emerging in diabetes care, sleep apnea, cardiovascular monitoring, and even ophthalmic devices. As these therapies become more widely used, they are changing referral patterns and reshaping the clinical pathways medtech companies must address.

Why it matters internationally: Obesity and metabolic disease are global epidemics, and GLP-1 drugs represent a pharmacological alternative that is scaling rapidly. While bariatric surgery remains the most effective intervention for substantial weight loss, the availability of GLP-1s is altering the economic calculus for providers and patients. Medtech companies must prepare for a future in which device markets are influenced by pharmaceutical trends.

5. Enabling Technologies: Platform-Based Competition Takes Center Stage

Robotics, imaging, navigation, and digital workflow software are no longer adjuncts to procedures—they are becoming the foundation of competitive strategy. Integrated platforms that span clinical planning, surgical execution, and postoperative care are creating lock-in effects and data-driven value propositions. Companies are investing heavily in open-platform architectures to increase flexibility and expand their ecosystems.

Why it matters internationally: Platform competition transcends borders. A company that establishes a dominant platform in one region can extend it globally, but faces varying regulatory and infrastructure requirements. International alliances and partnerships will be critical to bringing these technologies to emerging markets, where data infrastructure and training regimes may differ.

International Impact

These trends carry significant implications for the global economy, trade, and public health policy:

• Global economy: Pricing pressures in China are lowering device prices worldwide, affecting multinational revenues and profit margins. This could reduce investment in innovation but also drive efficiency.
• International business: Supply chain diversification will reshape global manufacturing footprints, with implications for FDI flows and regional development.
• Trade and investment: Tariffs and trade policies are becoming decisive factors in where medtech companies choose to produce and sell. Governments are increasingly linking market access to investment in local production.
• Public policy: Healthcare systems worldwide are grappling with how to integrate GLP-1 therapies while sustaining device coverage. Policymakers will need to balance innovation incentives with cost containment.
• Technology and governance: The rise of platform-based medtech raises concerns about data sovereignty, cybersecurity, and algorithmic bias, requiring international norms and cooperation.
• Climate transition: Medtech manufacturing is energy-intensive, and pressure to reduce emissions may intersect with supply chain reshoring, creating opportunities for sustainable production.

Strategic Perspectives

For business leaders, several strategic imperatives emerge from these trends:

• Rethink market access strategies in light of China’s VBP; consider local partnerships or premium product differentiation.
• Adapt commercial models to the outpatient setting, including new financing structures and service-based offerings.
• Build supply chain redundancy through nearshoring, multi-sourcing, and strategic stockpiling, while accepting higher costs.
• Monitor GLP-1 adoption and its impact on procedure volumes; adjust sales forecasting and R&D pipelines accordingly.
• Invest in integrated platforms that enhance customer stickiness and generate recurring data insights, but remain open to interoperability to avoid antitrust scrutiny.

Future Outlook

Looking ahead to the next 3–10 years, the medtech landscape will continue to evolve:

• Artificial intelligence and data analytics will become embedded in every device, enabling predictive maintenance, personalized treatment, and real-time population health insights.
• Global regulatory convergence may accelerate, but differences between major markets could create fragmentation.
• Emerging markets will become savvier buyers, leveraging volume-based procurement and local production requirements to build self-reliance.
• The convergence of medtech and pharma will intensify as companies seek to offer holistic metabolic health solutions.
• Supply chain networks will transform into hyperlocal, digitalized ecosystems that are more resilient but require greater capital investment.
• Platform-based ecosystems will become the primary mode of competition, with scale dictating access to capital, data, and talent.

Conclusion

The medtech industry is at a pivotal juncture. The trends shaping 2026 are not merely temporary disruptions but indicators of a fundamental structural transformation. Companies that recognize the international dimension of these forces—and adapt their strategies accordingly—will be better positioned to thrive in a world where price pressures, care delivery innovations, and geopolitical realities converge. For policymakers and investors, the message is clear: the future of medical technology is being defined by global dynamics, and strategic foresight is essential.

Key Takeaways

• China’s VBP program is redefining global pricing benchmarks and accelerating domestic innovation.
• The shift to outpatient and ASC settings is transforming procedure economics and requires new commercial models.
• Supply chain resilience is now a strategic imperative, influenced by tariffs and geopolitical risk.
• GLP-1 therapies are altering procedure volumes across multiple medtech categories.
• Platform-based competition is emerging as the key differentiator, integrating robotics, imaging, and data analytics.

Sources

• Clarivate, "5 medtech trends to watch in 2026," https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026